External broker reports(aggregated public sources), Axis Direct

Axis Direct

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only.  Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<div><ul><li>Aarti Drugs’ reported Q1FY24 results stood below our expectations due to a fall in exports which comprised Formulations (+6%YoY) and Speciality Chemical segment (-18% YoY).</li><li>Its reported revenue stood at Rs 661 Cr, up 6.3% YoY and the growth was led by the API segment which grew by 9% YoY.</li><li>There has been a good pick up in the API volume offtake in the domestic market at 18% but realisations declined by 8% on a YoY basis.</li></ul></div><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Aarti Drugs’ reported Q1FY24 results stood below our expectations due to a fall in exports which comprised Formulations (+6%YoY) and Speciality Chemical segment (-18% YoY).Its reported revenue stood at Rs 661 Cr, up 6.3% YoY and the growth was led by the API segment which grew by 9% YoY.There has been a good pick up in the API volume offtake in the domestic market at 18% but realisations declined by 8% on a YoY basis.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Aarti Drugs Ltd - Volume Growth Offset by Low Realizations